Ellis M - Search Results

1

PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.

Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, Welch MJ, Siegel BA. Dehdashti F, et al. Among authors: ellis m. Breast Cancer Res Treat. 2009 Feb;113(3):509-17. doi: 10.1007/s10549-008-9953-0. Epub 2008 Mar 9. Breast Cancer Res Treat. 2009. PMID: 18327670 Free PMC article.

2

Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.

Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR. Ellis MJ, et al. Cancer Res. 2003 Oct 1;63(19):6523-31. Cancer Res. 2003. PMID: 14559846 Clinical Trial.

3

Neoadjuvant endocrine therapy as a drug development strategy.

Ellis MJ. Ellis MJ. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):391S-5S. doi: 10.1158/1078-0432.ccr-031202. Clin Cancer Res. 2004. PMID: 14734497

4

Overcoming endocrine therapy resistance by signal transduction inhibition.

Ellis M. Ellis M. Oncologist. 2004;9 Suppl 3:20-6. doi: 10.1634/theoncologist.9-suppl_3-20. Oncologist. 2004. PMID: 15163844 Free article. Review.

5

Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.

Crowder RJ, Ellis MJ. Crowder RJ, et al. Breast Cancer Res. 2005;7(5):212-4. doi: 10.1186/bcr1307. Epub 2005 Aug 5. Breast Cancer Res. 2005. PMID: 16168140 Free PMC article.

6

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.

Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Ellis MJ, et al. J Clin Oncol. 2006 Jul 1;24(19):3019-25. doi: 10.1200/JCO.2005.04.3034. Epub 2006 Jun 5. J Clin Oncol. 2006. PMID: 16754938

7

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.

Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. Marcom PK, et al. Breast Cancer Res Treat. 2007 Mar;102(1):43-9. doi: 10.1007/s10549-006-9307-8. Epub 2006 Aug 8. Breast Cancer Res Treat. 2007. PMID: 16897431 Clinical Trial.

8

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.

Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Harris LN, et al. Among authors: ellis m. Breast Cancer Res. 2006;8(6):R66. doi: 10.1186/bcr1622. Breast Cancer Res. 2006. PMID: 17129383 Free PMC article. Clinical Trial.

9

Neoadjuvant endocrine therapy for locally advanced breast cancer.

Ma CX, Ellis MJ. Ma CX, et al. Semin Oncol. 2006 Dec;33(6):650-6. doi: 10.1053/j.seminoncol.2006.08.013. Semin Oncol. 2006. PMID: 17145344 Review.

10

"I'm pregnant and I have breast cancer".

Naughton MJ, Ellis M. Naughton MJ, et al. Among authors: ellis m. BMC Cancer. 2007 May 30;7:93. doi: 10.1186/1471-2407-7-93. BMC Cancer. 2007. PMID: 17537242 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,397 results

Search Page

Filters